GILD
GILEAD SCIENCES, INC.Evidence as of 2026-09-09The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on GILD
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · GILEAD SCIENCES, INC.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease…
Management team
- Ms. Diane E. Wilfong · Interim Corporate Controller, Chief Accounting Officer & Principal Accounting OfficerFind on LinkedIn
- Ms. Johanna Mercier · Chief Commercial OfficerFind on LinkedIn
- Ms. Deborah H. Telman J.D. · Executive VP of Corporate Affairs, General Counsel & Corporate SecretaryFind on LinkedIn
- Mr. Andrew D. Dickinson · Chief Financial OfficerFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.5 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The surviving evidence yields a cautious balance ( -0.5 of +2; confidence high). On a quarterly level, reported revenue was roughly flat-to-moderately variable across the sampled periods: $ 7,082,000,000 (fiscal Q1 2025), $ 7,769,000,000 (Q2 2025), $ 6,960,000,000 (Q1 2026), and $ 7,803,000,000 (Q2 2026). Operating results swung from positive operating income of $ 2,474,000,000 and $ 3,327,000,000 in fiscal Q1 and Q2 2025 to an operating loss of $ 10,394,000,000 in fiscal Q2 2026; net income and diluted EPS show the same pattern, with net losses of $ 10,496,000,000 and diluted loss per share of -$ 8.45 in fiscal Q2 2026 after positive earnings in prior quarters.
Capital and valuation evidence is mixed: trailing twelve‑month FCF is $ 7,829,000,000 with price‑to‑FCF at 23.28 and an implied FCF growth rate priced at 0.1273. Cash on the balance sheet is $ 5,412,000,000 versus long‑term debt of $ 26,246,000,000 as of 2026-06-30. Market signals show low market beta ( 0.35 ), recent bullish technicals (golden cross true; price +7.1% vs SMA50), elevated volatility ( 28.4% annualized; 90th percentile), and notable historical drawdown metrics ( max_drawdown_3y -26.6%, drawdown_from_3y_high -4.7%). Filings add concentrated U.S. wholesale channel risk, new operational risk language around CAR T manufacturing and supply chain, and REMS‑related discussion; several recent insider Form 4s and ETF/institutional holdings activity are also recorded.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Revenue was $7,082,000,000 for the period 2025-04-01 to 2025-06-30 (3mo).
XBRL companyfacts · 0000882095-25-000032Revenue was $7,769,000,000 for the period 2025-07-01 to 2025-09-30 (3mo).
XBRL companyfacts · 0000882095-25-000047Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
The 10-K filed 24 February 2026 added explicit risk language about operational challenges in advancing CAR T-cell therapies, including engineering patient T cells, conditioning patients with chemotherapy, and securing sufficient supplies of supportive medications such as tocilizumab and corticosteroids.
10-K filed 2026-02-24The 10-K filed 24 February 2026 added a discussion that future cell therapy products may be subject to a REMS, and noted that Yescarta and Tecartus were subject to a REMS requirement until June 2025.
10-K filed 2026-02-24Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
Beta vs SPY is 0.35 and correlation with SPY is 0.17, indicating low sensitivity and low linear co-movement with the broad market as of 2026-09-08.
Moneyta signal set · 2026-09-08Shorter-term momentum measures show mixed strength: momentum_3m is +15.2% while momentum_6m is +1.2%, with the 6-month momentum at the 37th percentile of the 548-stock research universe.
Moneyta signal set · 2026-09-08weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
13F-reported institutional holdings totaled $448.6M as of 2026-03-31, with 7 reporting holders, 5 new positions, and a quarter-over-quarter reported value change of 70.7%.
13F holdings · 7 filers · as of 2026-03-31GILD is a material holding in the healthcare ETF XLV at 2.82% of that fund as of 2026-09-02, and also appears in broad and value ETFs (VYM 0.72%, VTV 0.53%, SCHX 0.26%, IVV 0.24%, SCHB 0.24%, VOO 0.23%) as of the same dates.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
On 8 September 2026 several headlines noted Gilead's share price fell more than the broader market at the close of the trading day.
News · finance.yahoo.com · 2026-09-08On 8 September 2026 at least two outlets carried a company announcement that Assembly Biosciences will share 40% of U.S. development costs and profits with Gilead for the helicase-primase inhibitor program for recurrent genital herpes, and the deal includes a first $75 million collaboration extension fee from Gilead payable in Q4 2026.
News · finance.yahoo.com · 2026-09-08Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Daniel Patrick O'Day (Chairman & CEO) reported three sales on 2026-09-01 totaling $2,244k for 15,000 shares; the filing states the trades were made under a 10b5-1 plan.
Form 4 · O'Day Daniel Patrick (Chairman & CEO) · $236k sold · 2026-09-01Anthony Welters (Director) reported multiple transactions on 2026-08-26 that together report $3,750k in proceeds for 36,000 shares, and the filing indicates the trades were made under a 10b5-1 plan.
Form 4 · WELTERS ANTHONY (Director) · $468k code M · 2026-08-26Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model-backed implied free cash flow (FCF) growth rate that today's price would justify is 12.73% (0.1273).
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve-month free cash flow (FCF) is $7,829,000,000.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
Several pieces of evidence jointly support a favorable read: sequential quarterly revenue and earlier-quarter profitability data show recurring topline scale and prior operating/net income (fundamentals-0..6, 8..10, 12..14), trailing twelve-month free cash flow is sizable (valuation-1), and market signals show positive longer-term momentum and bullish technicals (market-2, market-3). Institutional and ETF ownership data indicate visible demand and positioning from professional investors (ownership-0, ownership-1), and recent corporate announcements around the Assembly collaboration and a new research center are concrete operational developments (news-1, news-2, news-3). These items together weaken a bear reading that relies solely on the single large Q2 2026 accounting loss by showing that (a) losses appear concentrated in one reported quarter while prior quarters reported operating profit and net income, and (b) cash-generation and market positioning remain meaningful. Evidence strength: the quarter-by-quarter fundamentals and FCF figures are high-quality (SEC filings and valuation model outputs), momentum/technical signals are medium-strength market-data signals, and the deal/press announcements are primary-release strength.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.46
56 surviving claims rest on 21 distinct sources; the heaviest analyst carries 48% of them, and 98% of what the desk raised survived the debate.
The evidence set rests on a moderate spread of sources but a large fraction of surviving claims trace back to a single analyst’s work, and almost everything the desk raised survived peer challenge. That pattern raises confidence in the desk’s internal consistency but flags vulnerability: source-concentration and analyst-dependence mean a single correction or restatement could materially change the read; high survival through debate suggests robustness of the current narrative, not immunity to new primary-document updates.
Peer context · computed, not argued
12-1 momentum ranks 8th of 10 in Drug Manufacturers—General (as of 2026-09-08).
90-day volatility ranks 6th of 10 in Drug Manufacturers—General (as of 2026-09-08).
dividend yield ranks 8th of 10 in Drug Manufacturers—General (as of 2026-09-08).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
12 filings· 3 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer−0.2 to the score
9 documents· 3 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−0.8 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.3 to the score
3 holdings records· 2 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.7 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
4 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot−1.0 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on GILD Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.